Latest news with #NikhilLalwani
Yahoo
27-05-2025
- Business
- Yahoo
ANI Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference
PRINCETON, N.J., May 27, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, will present at the 2025 Jefferies Global Healthcare Conference in New York City as follows: Date: Wednesday, June 4, 2025 Time: 2:35pm ET Webcast: Click Here To schedule a 1x1 meeting with the Company, please contact your Jefferies representative at healthcareconference@ The live and archived webcast will be accessible from the Company's website at under the Investors section under Events and Presentations. The replay of the webcast will be accessible for 60 days. About ANI Pharmaceuticals, Inc. ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company committed to its mission of 'Serving Patients, Improving Lives" by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable growth through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; its Generics business, which leverages R&D expertise, operational excellence, and U.S.-based manufacturing; and its Brands business. For more information, visit Investor Relations: Lisa M. Wilson, In-Site Communications, Inc.T: 212-452-2793 E: lwilson@ Source: ANI Pharmaceuticals, in to access your portfolio
Yahoo
13-05-2025
- Business
- Yahoo
ANI Pharmaceuticals to Participate at the H.C. Wainwright 3rd Annual BioConnect Conference at NASDAQ
PRINCETON, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ as follows: Date: Tuesday, May 20, 2025 Time: 1:30pm ET Webcast: Click Here To schedule a 1x1 meeting with management, please contact meetings@ The live and archived webcast will be accessible from the Company's website at under the Investors section under Events and Presentations. The replay of the webcast will be accessible for 90 days. About ANI ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company committed to its mission of 'Serving Patients, Improving Lives" by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable growth through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; its Generics business, which leverages R&D expertise, operational excellence, and U.S.-based manufacturing; and its Brands business. For more information, visit Investor Relations: Lisa M. Wilson, In-Site Communications, Inc.T: 212-452-2793 E: lwilson@ Source: ANI Pharmaceuticals, Inc.
Yahoo
12-05-2025
- Business
- Yahoo
ANI Pharmaceuticals to Participate at the H.C. Wainwright 3rd Annual BioConnect Conference at NASDAQ
PRINCETON, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ as follows: Date: Tuesday, May 20, 2025 Time: 1:30pm ET Webcast: Click Here To schedule a 1x1 meeting with management, please contact meetings@ The live and archived webcast will be accessible from the Company's website at under the Investors section under Events and Presentations. The replay of the webcast will be accessible for 90 days. About ANI ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company committed to its mission of 'Serving Patients, Improving Lives" by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable growth through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; its Generics business, which leverages R&D expertise, operational excellence, and U.S.-based manufacturing; and its Brands business. For more information, visit Investor Relations: Lisa M. Wilson, In-Site Communications, Inc.T: 212-452-2793 E: lwilson@ Source: ANI Pharmaceuticals, in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
09-05-2025
- Business
- Yahoo
ANI Pharmaceuticals (NASDAQ:ANIP) Reports Strong Q1, Full-Year Outlook Slightly Exceeds Expectations
Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) reported Q1 CY2025 results exceeding the market's revenue expectations , with sales up 43.4% year on year to $197.1 million. The company's full-year revenue guidance of $780.5 million at the midpoint came in 1.4% above analysts' estimates. Its non-GAAP profit of $1.70 per share was 23% above analysts' consensus estimates. Is now the time to buy ANI Pharmaceuticals? Find out in our full research report. Revenue: $197.1 million vs analyst estimates of $179.6 million (43.4% year-on-year growth, 9.8% beat) Adjusted EPS: $1.70 vs analyst estimates of $1.38 (23% beat) Adjusted EBITDA: $50.75 million vs analyst estimates of $42.4 million (25.7% margin, 19.7% beat) The company lifted its revenue guidance for the full year to $780.5 million at the midpoint from $766 million, a 1.9% increase Management raised its full-year Adjusted EPS guidance to $6.45 at the midpoint, a 2.2% increase EBITDA guidance for the full year is $200 million at the midpoint, above analyst estimates of $195.8 million Operating Margin: 13.3%, down from 14.8% in the same quarter last year Market Capitalization: $1.45 billion 'We are pleased to report another strong quarter, with record revenue, adjusted EBITDA and adjusted EPS driven by continued strong demand for Cortrophin Gel, exceptional performance for our Generics business, and increased demand for our Brands portfolio,' said Nikhil Lalwani, President and CEO of ANI. With a diverse portfolio of 116 pharmaceutical products and a growing rare disease platform, ANI Pharmaceuticals (NASDAQ:ANIP) develops, manufactures, and markets branded and generic prescription pharmaceuticals, with a focus on rare disease treatments. Reviewing a company's long-term sales performance reveals insights into its quality. Any business can have short-term success, but a top-tier one grows for years. Over the last five years, ANI Pharmaceuticals grew its sales at an exceptional 27.1% compounded annual growth rate. Its growth beat the average healthcare company and shows its offerings resonate with customers. We at StockStory place the most emphasis on long-term growth, but within healthcare, a half-decade historical view may miss recent innovations or disruptive industry trends. ANI Pharmaceuticals's annualized revenue growth of 37.1% over the last two years is above its five-year trend, suggesting its demand was strong and recently accelerated. This quarter, ANI Pharmaceuticals reported magnificent year-on-year revenue growth of 43.4%, and its $197.1 million of revenue beat Wall Street's estimates by 9.8%. Looking ahead, sell-side analysts expect revenue to grow 16.2% over the next 12 months, a deceleration versus the last two years. Despite the slowdown, this projection is commendable and implies the market sees success for its products and services. Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) stock benefiting from the rise of AI. Click here to access our free report one of our favorites growth stories. Operating margin is one of the best measures of profitability because it tells us how much money a company takes home after subtracting all core expenses, like marketing and R&D. ANI Pharmaceuticals was roughly breakeven when averaging the last five years of quarterly operating profits, lousy for a healthcare business. On the plus side, ANI Pharmaceuticals's operating margin rose by 3.4 percentage points over the last five years, as its sales growth gave it operating leverage. The company's two-year trajectory shows its performance was mostly driven by its recent improvements. In Q1, ANI Pharmaceuticals generated an operating profit margin of 13.3%, down 1.5 percentage points year on year. This reduction is quite minuscule and indicates the company's overall cost structure has been relatively stable. We track the long-term change in earnings per share (EPS) for the same reason as long-term revenue growth. Compared to revenue, however, EPS highlights whether a company's growth is profitable. ANI Pharmaceuticals's EPS grew at an unimpressive 3.5% compounded annual growth rate over the last five years, lower than its 27.1% annualized revenue growth. However, its operating margin actually expanded during this time, telling us that non-fundamental factors such as interest expenses and taxes affected its ultimate earnings. We can take a deeper look into ANI Pharmaceuticals's earnings to better understand the drivers of its performance. A five-year view shows ANI Pharmaceuticals has diluted its shareholders, growing its share count by 68.4%. This dilution overshadowed its increased operating efficiency and has led to lower per share earnings. Taxes and interest expenses can also affect EPS but don't tell us as much about a company's fundamentals. In Q1, ANI Pharmaceuticals reported EPS at $1.70, up from $1.21 in the same quarter last year. This print easily cleared analysts' estimates, and shareholders should be content with the results. Over the next 12 months, Wall Street expects ANI Pharmaceuticals's full-year EPS of $5.69 to grow 13.1%. We were impressed by how significantly ANI Pharmaceuticals blew past analysts' revenue, EPS, and EBITDA expectations this quarter. We were also glad it raised it full-year guidance across all three metrics. Zooming out, we think this was a solid "beat-and-raise" quarter. The stock traded up 4.2% to $74.69 immediately following the results. ANI Pharmaceuticals may have had a good quarter, but does that mean you should invest right now? If you're making that decision, you should consider the bigger picture of valuation, business qualities, as well as the latest earnings. We cover that in our actionable full research report which you can read here, it's free.
Yahoo
09-05-2025
- Business
- Yahoo
Cortrophin Demand Is Soaring For ANI Pharma, CEO Says Well-Positioned To Mitigate Potential Tariff Impact
ANI Pharmaceuticals Inc (NASDAQ:ANIP) reported first-quarter adjusted earnings of $1.70 per share on Friday, up from $1.21 a year ago, beating the consensus of $1.38 per share. The company reported sales of $197.12 million, up 43.4% year over year, beating the consensus of $180.68 million. On an organic basis, excluding the acquisition of Alimera, total net revenues grew 31.7% year-over-year. Net revenues for rare diseases, which include Cortrophin gel, Iluvien, and Yutiq, increased by 86.7% to $69.0 million. Cortrophin Gel net revenues increased 43.1% to $52.9 million, driven by increased the quarter, the company saw increasing demand with the highest number of new patient starts and new cases initiated since launch. Cortrophin Gel experienced growth across existing and new prescribers, and ANI continued to expand the overall base of Cortrophin Gel prescribers. Iluvien and Yutiq generated net revenues of $16.1 million. Performance for retina assets outside the U.S. was in line with expectations. Performance in the U.S. was impacted by reduced access for Medicare patients due to a lack of funding for third-party co-pay assistance programs, turnover in our sales force, and seasonality. Brands' net revenues decreased 2.2% to $25.1 million, driven by a modest net decrease in volume. Net revenues for Generic pharmaceutical products increased 40.5% to $98.7 million, driven by increased volumes in the base business and contributions from new product launches. Reported gross margin decreased from 64.2% to 62.9%. Adjusted gross margin decreased from 64.4% to 63.1%, primarily due to mix, including significant growth of royalty-bearing products, including Cortrophin Gel. Nikhil Lalwani, President and CEO, commented, 'Based on our first quarter performance and favorable demand trends for Cortrophin Gel and our Generics and Brands portfolio, we are raising our 2025 guidance for total revenues, adjusted non-GAAP EBITDA, and adjusted non-GAAP EPS. While we await more visibility on potential pharmaceutical industry-specific tariffs, we believe we are well-positioned based on our strong U.S. footprint with over 90% of our revenues coming from finished goods manufactured in the U.S. and less than 5% of our revenues with direct reliance on China.' Guidance: ANI Pharmaceuticals raised its 2025 revenue guidance from $756 million to $776 million to $768 million to $793 million, versus the consensus of $769.64 million. The company expects adjusted EBITDA of $195 million to $205 million compared to prior guidance of $190 million to $200 million. ANI Pharmaceuticals expects 2025 adjusted EPS of $6.27 to $6.62 versus prior guidance of $6.12 to $6.49 and a consensus of $6.34. Price Action: ANIP stock is down 4.95% to $67.99 at the last check on A Recession, These Waste Management Stocks Have Outperformed S&P 500 Historically Image by JHVEPhoto via Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? ANI PHARMACEUTICALS (ANIP): Free Stock Analysis Report This article Cortrophin Demand Is Soaring For ANI Pharma, CEO Says Well-Positioned To Mitigate Potential Tariff Impact originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved.
